$IPHA Innate Pharma Exploding! 🚀 Up 62% 🔹 Huge move after Q1 update showed progress across multiple oncology programs 📈 🔹 Lacutamab Phase 3 TELLOMAK-3 trial

$IPHA Innate Pharma Exploding! 🚀 Up 62% 🔹 Huge move after Q1 update showed progress across multiple oncology programs 📈 🔹 Lacutamab Phase 3 TELLOMAK-3 trial remains planned for H2 2026 🔥 🔹 IPH4502 continues showing preliminary anti-tumor activity with a favorable safety profile to date 🧬 🔹 A…